ACME Bioscience Inc.

ACME Bioscience Inc. is a biopharmaceutical service provider that specializes in comprehensive chemistry solutions, including medicinal chemistry and chemical manufacturing, aimed at enhancing drug discovery and development for global pharmaceutical companies. ACME Bioscience Inc. , founded in 2001, is headquartered in Palo Alto, US.

The company specializes in chemistry services for the biopharmaceutical industry. In July 2020, Frontage Holdings Corporation acquired ACME Bioscience, marking a strategic pivot in its operations to align with Frontage's portfolio. The CEO is Jason Zhang. ACME Bioscience, a subsidiary of Frontage Holdings Corporation, specializes in providing a comprehensive suite of chemistry services for the biopharmaceutical industry.

The company's core offerings include discovery chemistry, medicinal chemistry, process chemistry research and development, and chemical manufacturing services. Acme's expertise covers a wide array of specialties, particularly in antiviral and antibacterial research, while also focusing on nucleotides, nucleosides, triphosphates pro-drugs, heterocycles, and boron-containing compounds. These services are aimed at biopharmaceutical companies seeking to develop new chemical entities, with Acme acting as a collaborative partner to enhance the efficiency and effectiveness of the drug discovery process. Acme Bioscience serves a diverse clientele across North America, Europe, and Asia, meeting the needs of global pharmaceutical companies that require high-quality chemistry research and development support.

ACME Bioscience's revenue generation is primarily driven by its contract research services, which operate on a B2B model. Clients engage Acme through tailored contracts that specify the scope and timeline of research projects, with the potential for ongoing partnerships as projects expand. Revenue is generated through various types of agreements, including fee-for-service arrangements where clients pay for specific services rendered, and long-term collaborations that may involve phased payments based on project milestones. The firm’s offerings, including their medicinal chemistry and process development services, are priced according to the complexity and duration of the project, ensuring that clients receive value aligned with their specific research needs.

This structured transaction model facilitates strong relationships with pharmaceutical and biotechnology companies, enhancing Acme's reputation and positioning within the industry. Following its acquisition by Frontage Holdings Corporation in July 2020, ACME Bioscience is set to expand its offerings and geographic reach. The company aims to launch new chemistry services tailored for emerging markets in Asia and Europe by 2023. Recent funding from this acquisition will support the development of these new services and facilitate entry into these targeted markets.